Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV-1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFN alpha vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFN alpha Abs (whether under HAART or not) when compared to placebo or non-responder vaccinees, a strong correlation was found between an increased IFN alpha neutralizing capacity and the reduction of clinical manifestations.
Zagury
D
D
Laboratoire de Physiologie Cellulaire, P. et M. Curie University, Paris, France.
Lecoq
H
H
Gervi
I
I
Le Buanec
H
H
Zagury
J F
JF
Bizzini
B
B
Burny
A
A
Hermans
P
P
Perja
M
M
Santagostino
E
E
Gringeri
A
A
D016915:AIDS Vaccines / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000276:immunology*; D017024:Chemotherapy, Adjuvant; D004311:Double-Blind Method; D015658:HIV Infections / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007114:Immunization; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology*; D011994:Recombinant Proteins; D014612:Vaccines / Q000627:therapeutic use*
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D001323:Autoantibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014612:Vaccines